PLUR vs. CASI, INAB, INKT, ACHL, TARA, NKGN, AIM, CYTH, TVGN, and EVAX
Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include CASI Pharmaceuticals (CASI), IN8bio (INAB), MiNK Therapeutics (INKT), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), NKGen Biotech (NKGN), AIM ImmunoTech (AIM), Cyclo Therapeutics (CYTH), Tevogen Bio (TVGN), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
CASI Pharmaceuticals (NASDAQ:CASI) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
CASI Pharmaceuticals has higher revenue and earnings than Pluri. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
CASI Pharmaceuticals has a net margin of -79.30% compared to CASI Pharmaceuticals' net margin of -6,708.40%. Pluri's return on equity of -77.55% beat CASI Pharmaceuticals' return on equity.
22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
CASI Pharmaceuticals received 199 more outperform votes than Pluri when rated by MarketBeat users.
In the previous week, CASI Pharmaceuticals had 2 more articles in the media than Pluri. MarketBeat recorded 3 mentions for CASI Pharmaceuticals and 1 mentions for Pluri. Pluri's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.
CASI Pharmaceuticals presently has a consensus price target of $12.00, suggesting a potential upside of 378.09%. Given Pluri's higher possible upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Pluri.
Summary
CASI Pharmaceuticals beats Pluri on 11 of the 14 factors compared between the two stocks.
Get Pluri News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
